PALMELLE
 Read · Healthcare Policy
CMS Surprise: 2.48% Medicare Advantage Boost Fuels Insurer Profits, Not Patient Savings
Healthcare Policy

CMS Surprise: 2.48% Medicare Advantage Boost Fuels Insurer Profits, Not Patient Savings

While official narratives tout lower drug costs, a closer look at the CMS payment rule reveals a significant financial uplift for health giants, potentially at your expense.

By Neil D'Monte, Palmelle Editorial Team · Reviewed by Neil D'Monte · 7 min read · 2026-07-14
SHORT ANSWER
CMS finalized a 2.48% payment increase for Medicare Advantage plans in 2027, amounting to over $13 billion in additional payments, a much higher figure than anticipated, which is expected to benefit insurers significantly.

The direct answer

The Centers for Medicare & Medicaid Services (CMS) has finalized its payment policies for Medicare Advantage (MA) and Part D for 2027, projecting an average net increase of 2.48%

. This figure, translating to over $13 billion in additional payments to MA plans, significantly surpasses initial expectations that hovered around 1.0%

. While CMS also announced initiatives to lower prescription drug costs and expanded site-neutral payment policies for hospital outpatient departments, the headline rate increase for MA plans has sent shockwaves through the industry, with major players like UnitedHealth Group ($UNH) seeing immediate after-hours gains

. This substantial financial injection into MA plans raises questions about whether these funds will translate into better benefits or lower costs for beneficiaries, or primarily serve to boost insurer profitability.

The 'Better-Than-Expected' Rate Hike: What It Really Means

The conventional wisdom might suggest a 2.48% payment increase from CMS is simply an adjustment, but the reality is far more impactful. This figure represents a substantial financial uplift for Medicare Advantage plans, projected to inject over $13 billion into the sector

. Many analysts and industry insiders were bracing for a much smaller increase, around 1.0%

. The fact that CMS finalized a rate significantly higher than anticipated is a direct tailwind for major health insurers like UnitedHealth Group ($UNH), Humana ($HUM), and CVS ($CVS), whose stock prices often react swiftly to such news [c2, c4]. This isn't just a number; it's a direct financial injection that could influence insurer strategies, benefit packages, and ultimately, the out-of-pocket costs for millions of Medicare beneficiaries.

Site-Neutral Payments and Drug Costs: A Calculated Diversion?

While the headline-grabbing MA payment increase dominates the conversation, CMS also proposed expanded site-neutral payment policies and initiatives aimed at lowering prescription drug costs. Site-neutral payments, in theory, mean Medicare pays the same for a service regardless of where it's performed (e.g., a hospital outpatient department vs. an independent clinic). This is often framed as a cost-saving measure for Medicare. However, the simultaneous, substantial increase in MA payments suggests a complex balancing act, or perhaps a strategic redirection of funds. The focus on prescription drug costs, while laudable, needs scrutiny: will these initiatives genuinely reduce what seniors pay at the pharmacy, or will they be overshadowed by the increased revenue flowing directly to MA plans?

The Risk Adjustment Model: A Boon for Insurers

A critical, yet often overlooked, component of the CMS announcement is the decision to maintain the 2024 Medicare Advantage risk adjustment model and exclude most unlinked chart review diagnoses from risk calculations

. Risk adjustment is how MA plans are paid based on the expected healthcare costs of their enrollees. By keeping the existing model and excluding certain diagnoses, CMS is effectively preserving a system that has been beneficial to insurers. This move, coupled with the higher payment rate, reinforces the financial advantage for MA providers, ensuring they continue to receive robust payments that account for the health status of their members, without potentially facing adjustments for less rigorously documented conditions.

Common mistakes

PALMELLE'S VIEW
In our view, the much-hyped 2.48% Medicare Advantage payment increase for 2027 is less about improving beneficiary care and more about a significant financial windfall for health insurers. While CMS gestures towards prescription drug cost reduction, the substantial boost in MA reimbursement, far exceeding industry predictions

, directly benefits the large publicly traded companies that dominate the Medicare Advantage market

. This isn't about patient savings; it's about market dynamics and provider reimbursement. The agency's decision to maintain the 2024 MA risk adjustment model and exclude certain diagnoses from risk calculations

further suggests a focus on financial stability for insurers rather than direct cost savings for seniors.

BOTTOM LINE
Review your Medicare Advantage plan's 2027 Summary of Benefits and Annual Notice of Changes when they arrive to understand how the 2.48% payment increase might affect your specific copays and prescription drug costs.
WHEN THIS CHANGES
The financial implications for Medicare beneficiaries will become clearer as individual Medicare Advantage plans announce their 2027 benefit structures and formularies. Pay attention to specific changes in copays, deductibles, and prescription drug coverage starting in January 2027. The actual impact of site-neutral policies on service availability and cost will also depend on how providers and insurers adapt their operations and pricing.

Frequently asked

What is the main financial impact of the CMS announcement for Medicare Advantage plans?

CMS finalized a projected net average payment increase of 2.48% for Medicare Advantage plans in 2027. This translates to over $13 billion in additional payments to these plans, a figure significantly higher than many in the industry were anticipating.

Will this CMS announcement lower my prescription drug costs?

CMS has announced initiatives aimed at lowering prescription drug costs, but the direct impact on your out-of-pocket expenses is not yet clear. The substantial increase in payments to Medicare Advantage plans may overshadow these drug cost efforts for some beneficiaries.

How does this affect my access to outpatient services?

CMS proposed expanded site-neutral payment policies, which could affect how hospitals are reimbursed for outpatient services. The full implications for patient costs and provider access are still unfolding, but the primary financial takeaway is the significant MA payment boost.

Sources

  1. Stocker-Man X Post
  2. Casey | Trade Tracs X Post
  3. Wall St Engine X Post
  4. TrendSpider X Post

Keep reading

Healthcare PolicyHHS Scraps Nursing Home Staffing Mandate, Rural Facilities Breathe a Sigh of ReliefHealthcare PolicyState Nursing Home Mandates Succeed Where Federal Rule Failed: No Financial Harm FoundHealthcare PolicyMedicare Advantage Gets a $13 Billion Boost: Is Your Coverage Getting Better or Pricier?Healthcare PolicyMedicare's Big Shift: Your Doctor's Paycheck Is Changing, Not for the BetterHealthcare PolicyCMS Enrollment Shake-Up Will Reshape Senior Home Care: Are You Ready?Healthcare PolicyMedicare's Weight Loss Drug Gamble: A $50 Bet on a Costly Future

More from Healthcare Policy →   ·   Back to Perch   ·   Browse all stories